中药注射剂治疗心脑血管疾病系统评价/Meta分析的现状研究

来源 :药物流行病学杂志 | 被引量 : 0次 | 上传用户:liongliong570
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
目的:调查临床常用中药注射剂治疗心脑血管疾病系统评价/Meta分析的现状。方法:检索中国知网(CNKI,1979~2015年)和Pub Med(1990~2015年)文献数据库,筛选符合纳入标准的中药注射剂治疗心脑血管疾病的系统评价/Meta分析,提取有关信息,应用Microsoft Office 2010中Excel软件分析,并用AMSTAR和PRISMA量表对其方法学和发表质量进行评价。结果:纳入中药注射剂治疗心脑血管疾病类系统评价/Meta分析224篇,其中中文215篇,英文9篇,发表数量整体呈增长的趋势。出版刊物涉及93种期刊,其中篇数最多的是《中国中医急症》24篇(11.2%)。涉及中药注射剂30余品种,被评价次数最多的为参麦注射液17次(7.6%);用于治疗心血管疾病和脑血管疾病的临床评价数量相当。方法学质量、发表质量均以中等水平居多。结论:系统评价/Meta分析手段已得到较好的应用,为中药注射剂治疗心脑血管疾病临床循证决策提供了依据,但对中药注射剂的安全性问题鲜少涉及。因此,在今后的临床研究中,不仅需要进一步提高系统评价、临床试验水平,而且对中药注射剂治疗心脑血管疾病的有效性与安全性并重。 Objective: To investigate the status quo of systematic reviews / meta-analysis of commonly used traditional Chinese medicine injections in the treatment of cardiovascular and cerebrovascular diseases. METHODS: The literature databases of CNKI (CNKI, 1979-2015) and Pub Med (1990-2015) were searched. Systematic reviews / meta-analyzes of TCM injections that met the inclusion criteria were screened, and relevant information was extracted Excel software analysis in Microsoft Office 2010 and its methodology and publication quality using the AMSTAR and PRISMA scales. Results: A total of 224 systematic reviews / meta-analyzes of Chinese medicine injection for cardiovascular and cerebrovascular diseases were included, of which 215 were in Chinese and 9 were in English. The published numbers showed an overall trend of increase. The publications cover 93 journals, of which 24 are the largest in China (11.2%). More than 30 varieties of traditional Chinese medicine injections were involved, and the most frequently evaluated patients were Shenmai injection 17 times (7.6%). The clinical evaluations for treating cardiovascular diseases and cerebrovascular diseases were quite similar. Methodological quality, published quality are mostly middle level. Conclusion: The systematic reviews / meta-analyzes have been applied well and provided a basis for clinical evidence-based decision-making of Chinese medicine injection for the treatment of cardiovascular and cerebrovascular diseases. However, the safety of traditional Chinese medicine injections is rarely involved. Therefore, in the future clinical research, not only need to further improve the system evaluation, clinical trial level, but also the efficacy and safety of TCM injection for the treatment of cardiovascular and cerebrovascular diseases.
其他文献
患者,男,76岁,体重52 kg。因“反复活动后胸闷气促1月余,加重伴胸痛1周”入院。患者既往有冠心病、消化道溃疡、慢性肾功能不全病史。入院体检:T 36.5℃,P 76次/min,BP 98/68
期刊
@@
Winter cabbage is an important crop cultivated through winter in the region near the Yangtze River,enabling the supply of fresh cabbage there at that time of ye
[Objective]To study the apoptosis of CT26 cells of mouse colon cancer induced by the vombination of arsenic trioxide(As2O3)and paclitaxel(PTX) and to research i
Long terminal repeat retrotransposons (LTR-RTs) are a predominant group of plant transposable elements (TEs) that are an important component of plant genomes.A
目的:分析清华大学附属北京市垂杨柳医院铜绿假单胞菌(PA)耐药率与抗菌药物用药频度(DDDs)的相关性,为临床合理使用抗菌药物提供依据。方法:回顾性调查我院2010~2015年分离出
目的:探究影响注射剂安全合理使用的相关因素,寻找切实有效的干预措施。方法:自行设计调查表,对随机抽取的地方人员和部队官兵共999人进行问卷调查,对调查结果进行统计分析。
目的:探讨鲍曼不动杆菌血流感染患者的临床特征、感染危险因素及细菌耐药性,为临床合理用药和控制医院感染提供指导。方法:回顾性分析某院2011~2014年鲍曼不动杆菌血流感染患
目的:观察双歧三联活菌辅助治疗对肝硬化患者肠道菌群、血浆内毒素及肠黏膜屏障功能的影响。方法:70例肝硬化患者随机分为对照组和观察组各35例。对照组患者给予对症支持治疗
二肽基肽酶Ⅳ(DPP-4)抑制药为新一代降糖药,随着该类药物的广泛使用,更多的不良反应已逐渐成为关注焦点.本文检索近年来国外DPP-4抑制药临床使用中不良反应的报道,并进行分析
患者,男,55岁,体重102 kg,因头痛1 d、意识不清7 h,于2016年1月29日以“梗阻性脑积水,鞍区占位”收入院。既往无家族性遗传史、食物药物过敏史。入院诊断:1梗阻性脑积水[非交
期刊
@@